CORT Corcept Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CORT

Price (delayed)

$110.51

Market cap

$11.95B

P/E Ratio

208.51

Dividend/share

N/A

EPS

$0.53

Enterprise value

$11.84B

?
Relative Growth: Rel. Growth: 77
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 45

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary ...

Highlights
The gross profit is up by 16% year-on-year and by 8% since the previous quarter
The revenue rose by 16% year-on-year and by 8% since the previous quarter
CORT's net income has shrunk by 59% YoY but it is up by 16% QoQ
The EPS has dropped by 58% year-on-year but it has grown by 15% since the previous quarter
The P/E is 124% more than the last 4 quarters average of 92.9
The quick ratio is down by 11% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corcept.com
Peers: JNJ BMY PFE LLY

Key stats

What are the main financial stats of CORT

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
-1.49%
1 week
2.37%
1 month
28.65%
1 year
51.8%
YTD
217.56%
QTD
27.1%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$830.81M
Gross profit
$816.73M
Operating income
$6.41M
Net income
$54.2M
Gross margin
98.3%
Net margin
6.5%
Corcept Therapeutics's operating income has soared by 178% from the previous quarter but it has plunged by 94% YoY
The operating margin has soared by 173% from the previous quarter but it has plunged by 94% YoY
Corcept Therapeutics's net margin has shrunk by 65% YoY but it has increased by 7% QoQ
CORT's net income has shrunk by 59% YoY but it is up by 16% QoQ

Price vs fundamentals

How does CORT's price correlate with its fundamentals

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
CORT P/E details
P/E
208.51
P/B
16.81
P/S
14.02
EV/EBIT
2,183.29
EV/EBITDA
1,509.79
EV/Sales
14.26
The P/E is 124% more than the last 4 quarters average of 92.9
The EPS has dropped by 58% year-on-year but it has grown by 15% since the previous quarter
The stock's price to book (P/B) is 124% more than its 5-year quarterly average of 7.5 and 70% more than its last 4 quarters average of 9.9
The company's equity rose by 11% YoY and by 11% QoQ
CORT's P/S is 89% above its 5-year quarterly average of 7.4 and 71% above its last 4 quarters average of 8.2
The revenue rose by 16% year-on-year and by 8% since the previous quarter

Efficiency

How efficient is Corcept Therapeutics business performance
The return on sales has surged by 158% since the previous quarter but it has dropped by 95% year-on-year
CORT's ROIC has soared by 156% since the previous quarter but it has dropped by 95% year-on-year
CORT's return on assets has dropped by 60% year-on-year but it is up by 12% since the previous quarter
The return on equity has dropped by 59% year-on-year but it is up by 14% since the previous quarter

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The company's total assets rose by 11% YoY and by 9% QoQ
The quick ratio is down by 11% year-on-year
Corcept Therapeutics's debt is 99% lower than its equity
CORT's debt to equity has shrunk by 50% QoQ
Corcept Therapeutics's debt has increased by 43% YoY but it has decreased by 2.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.